|
Gene: FAM227A |
Gene summary for FAM227A |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM227A | Gene ID | 646851 |
Gene name | family with sequence similarity 227 member A | |
Gene Alias | FAM227A | |
Cytomap | 22q13.1 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | F5H4B4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
646851 | FAM227A | HCC1_Meng | Human | Liver | HCC | 5.54e-12 | 1.03e-02 | 0.0246 |
646851 | FAM227A | HCC1 | Human | Liver | HCC | 5.60e-20 | 2.00e+00 | 0.5336 |
646851 | FAM227A | HCC2 | Human | Liver | HCC | 8.82e-36 | 3.14e+00 | 0.5341 |
646851 | FAM227A | HCC5 | Human | Liver | HCC | 2.25e-27 | 1.85e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM227A | SNV | Missense_Mutation | novel | c.296N>A | p.Ser99Tyr | p.S99Y | protein_coding | deleterious(0) | possibly_damaging(0.769) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
FAM227A | SNV | Missense_Mutation | novel | c.724C>A | p.Leu242Ile | p.L242I | protein_coding | deleterious(0.01) | possibly_damaging(0.723) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
FAM227A | SNV | Missense_Mutation | novel | c.1102N>G | p.Thr368Ala | p.T368A | protein_coding | tolerated(0.64) | benign(0.005) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FAM227A | SNV | Missense_Mutation | rs565247823 | c.1423C>T | p.Arg475Trp | p.R475W | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
FAM227A | SNV | Missense_Mutation | novel | c.1808N>T | p.Arg603Ile | p.R603I | protein_coding | deleterious_low_confidence(0) | benign(0.11) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM227A | SNV | Missense_Mutation | c.1409G>A | p.Cys470Tyr | p.C470Y | protein_coding | deleterious(0.02) | possibly_damaging(0.454) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FAM227A | SNV | Missense_Mutation | c.1630C>A | p.Leu544Ile | p.L544I | protein_coding | tolerated(0.39) | benign(0.018) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
FAM227A | SNV | Missense_Mutation | novel | c.1813C>T | p.Arg605Cys | p.R605C | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
FAM227A | SNV | Missense_Mutation | c.1379N>T | p.Thr460Met | p.T460M | protein_coding | deleterious(0.04) | benign(0.272) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | ||
FAM227A | SNV | Missense_Mutation | novel | c.1257N>G | p.Ile419Met | p.I419M | protein_coding | deleterious(0) | possibly_damaging(0.79) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |